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Tissue metabolite profiles for the 
characterisation of paediatric 
cerebellar tumours
Christopher D. Bennett1,2, Sarah E. Kohe1,2, Simrandip K. Gill1,2, Nigel P. Davies2,3, 
Martin Wilson4, Lisa C. D. Storer5, Timothy Ritzmann5, Simon M. L. Paine6, Ian S. Scott6, 
Ina Nicklaus-Wollenteit2, Daniel A. Tennant  7, Richard G. Grundy5 & Andrew C. Peet  1,2
Paediatric brain tumors are becoming well characterized due to large genomic and epigenomic 
studies. Metabolomics is a powerful analytical approach aiding in the characterization of tumors. 
This study shows that common cerebellar tumors have metabolite profiles sufficiently different to 
build accurate, robust diagnostic classifiers, and that the metabolite profiles can be used to assess 
differences in metabolism between the tumors. Tissue metabolite profiles were obtained from 
cerebellar ependymoma (n = 18), medulloblastoma (n = 36), pilocytic astrocytoma (n = 24) and 
atypical teratoid/rhabdoid tumors (n = 5) samples using HR-MAS. Quantified metabolites accurately 
discriminated the tumors; classification accuracies were 94% for ependymoma and medulloblastoma 
and 92% for pilocytic astrocytoma. Using current intraoperative examination the diagnostic accuracy 
was 72% for ependymoma, 90% for medulloblastoma and 89% for pilocytic astrocytoma. Elevated 
myo-inositol was characteristic of ependymoma whilst high taurine, phosphocholine and glycine 
distinguished medulloblastoma. Glutamine, hypotaurine and N-acetylaspartate (NAA) were increased 
in pilocytic astrocytoma. High lipids, phosphocholine and glutathione were important for separating 
ATRTs from medulloblastomas. This study demonstrates the ability of metabolic profiling by HR-MAS 
on small biopsy tissue samples to characterize these tumors. Analysis of tissue metabolite profiles has 
advantages in terms of minimal tissue pre-processing, short data acquisition time giving the potential 
to be used as part of a rapid diagnostic work-up.
Paediatric tumors of the central nervous system (CNS) are the most common solid cancers diagnosed in chil-
dren1. They are now the highest cause of cancer related deaths in this population, causing death in around a 
third of cases after 10 years1. In broad terms the treatment for these tumors is maximal safe resection followed 
by chemotherapy and/or radiotherapy as appropriate according to treatment protocols. Whilst there has been an 
improvement in survival over the past 40 years there have been fewer gains recently2 and there is a pressing need 
to elucidate the molecular pathology as well as identify biomarkers of diagnosis and prognosis of these tumors.
In children, approximately 50% of CNS tumors occur in the posterior fossa, with the cerebellum being the 
most common site. The three most common tumors arising in the cerebellum are pilocytic astrocytoma, medullo-
blastoma and ependymoma1. Other tumors can occur in the cerebellum, most notably atypical teratoid/rhabdoid 
tumors (ATRT)3. Paediatric brain tumors are becoming well characterized in terms of their genetic and epigenetic 
alterations and clinically relevant subgroups have been identified4–7. Metabolomics is a powerful characterizing 
feature of tumors that may have clinical value. In vivo magnetic resonance spectroscopy (MRS) has previously 
been used to characterize the metabolite profiles of paediatric cerebellar tumors, and reported differences in sev-
eral metabolites8. However, in vivo MRS produces low resolution spectra where high concentration metabolites 
dominate those of a lower concentration and makes quantification of overlapping resonances difficult.
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Highly detailed spectroscopic studies can be performed on surgically resected tissue using high-resolution 
magic-angle spinning magnetic resonance spectroscopy (HR-MAS). The combination of a stronger magnetic 
field, the ability to rapidly spin the sample at 54.7° with regard to the magnetic field and the proximity of the 
radiofrequency coils to the sample leads to greatly improved spectral resolution9 and accurate quantitation of 
low abundance metabolites not visible using MRS. HR-MAS has been used with great success to examine the 
metabolite profiles of a wide range of cancers including prostate10, breast11 and lung12 cancers, as well as brain 
tumors from children13 and adults14. Many metabolite concentrations measured by in vivo MRS have been shown 
to correlate with ex vivo HR-MAS15. Better characterization of paediatric brain tumor tissue metabolite profiles 
has the potential to be translated to in vivo MRS. Increased metabolite quantitative accuracy would provide clini-
cians with valuable diagnostic and prognostic information. Given that HR-MAS is able to rapidly characterize the 
metabolite profile of small surgically resected tissue samples without any complex preparation, it shows potential 
to aid the surgical management of patients undergoing surgery for cerebellar tumors in real time. The treatment 
protocol for each of the four tumors in this study are different, and so obtaining a real time diagnosis is crucial to 
a child’s treatment both in terms of maximizing surgical outcome and minimizing the delay between surgery and 
chemo- or radiotherapy, particularly for fast growing, aggressive tumors such as ATRTs. Therefore, the primary 
aim of this study is to examine the diagnostic ability of HR-MAS using biopsy tissue in a retrospective manner.
Metabolism is the result of expression of metabolic enzymes, which are altered by the tumorigenic drivers of 
the tumors16,17. The concentrations of the metabolites can provide an insight into how the metabolic pathways are 
altered, and identify potential targets to interfere with tumor metabolism. The secondary aim of this study is to 
identify metabolic pathways that are differentially activated between the three tumor types.
Methods and Materials
Acquisition of tissue. Frozen diagnostic cerebellar tumor tissue for 24 pilocytic astrocytomas, 36 medullo-
blastomas, 18 ependymomas and 5 atypical teratoid/rhabdoid tumors (ATRTs) were acquired from Birmingham 
Children’s Hospital (BCH) and the Children’s Cancer and Leukaemia Group (CCLG) tissue banks. This study has 
Research Ethical Committee approval (NRES East Midlands-Derby, 04/MRE04/41) and CCLG Biological Studies 
Committee approval. Informed consent was obtained from the patient or parent/legal guardian. All methods were 
carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by 
the University of Birmingham. Tissue was snap frozen in liquid nitrogen shortly after surgical resection, prior to 
tumor treatment and stored at −80 °C. The final diagnosis was made following full histopathological examination 
of the tissue including immunohistochemistry where required and reviewed and agreed upon by multi-discipli-
nary teams.
HRMAS preparation. HR-MAS was performed at the Henry Wellcome Building Biomolecular NMR 
Facility at the University of Birmingham. Tissue was cut with a scalpel over dry ice to fit into a 12 μl or 50 μl zirco-
nium rotor before being weighed. The internal standard 3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt 
(TMSP) (Cambridge Biosciences, Cambridge, UK) was added to the sample in a rotor dependent manner. 3 μl of 
standard was added to 12 μl rotors whilst 5 μl of standard was added to 50 μl rotors. D2O (Sigma Aldrich, Dorset, 
UK) was added to completely fill the rotor before it was fully assembled. The sample and rotor were kept cold over 
dry ice during preparation to prevent tissue degradation.
Spectra acquisition. Spectra were acquired using a Bruker Avance spectrometer (Bruker, Coventry, UK) 
with a magnetic field strength of 500 MHz fitted with a 4 mm three channel HCD HRMAS z-PFG band probe. 
The rotor was spun at a temperature of 4 °C to prevent metabolic activity and a frequency of 4800 Hz to remove 
spinning sidebands from the spectra. A NOESY pulse and acquire sequence was used with 2 s presaturation to 
suppress the water signal and a repetition time of 4 s. 256 or 512 averages were acquired for 50 μl and 12 μl rotors 
respectively. Using this protocol, an experiment with 256 averages was completed in 17 minutes.
Analysis. Free Induction Decays were Fourier transformed in Topsin 2.0 (Bruker, Coventry, UK) and the 
resulting spectra were imported into MestReNova 9.0.1 software suite (Mestrelab Research, Spain). To ensure 
quality control, the spectra were visually examined for a high signal to noise ratio, a well-defined TMSP peak and 
clear discrimination of the choline, phosphocholine and glycerophosphocholine peaks at 3.2–3.3 ppm. Based on 
in vivo 1H and 31P spectroscopy, normal tissue is expected to have a large NAA peak, small peaks corresponding 
to the choline containing compounds with a PCh/GPC ratio of 0.4, an intermediate creatine peak and very small 
lipid peaks8,18. Overall the metabolite profiles of these brain tumors differ greatly from normal brain tissue. The 
spectra were phased, baseline corrected and the chemical shift referenced with respect to TMSP at 0 ppm. Peaks 
were picked using the Global Spectral Deconvolution algorithm which improves the resolution of areas of the 
spectrum with overlapping resonances. Features were quantified by comparing the area of the peaks correspond-
ing to the respective metabolite to the area of the internal standard peak, taking into account the number of pro-
tons contributing to both the metabolite and standard signal. Thirty one features were assigned (26 metabolites 
and 5 lipid groups; Supplementary Table 2) to the spectra and raw metabolite concentrations were obtained using 
the qNMR function in MestReNova. Experimentally acquired chemical shift information from Govindaraju et 
al.19 and the Human Metabolome Database (HMDB)20 were used to confirm signal assignment. Due to the low 
proportion of the tumors in which n-acetylaspartylglutamate and acetone could be confidently identified, and 
due to lactate accumulation in the tissue over a variable amount of time during surgical excision, these three 
metabolites were excluded from further analysis. Prior to statistical analyses, lipid concentrations were summed 
and the data were normalized to the sum of total non-lipid metabolite concentrations.
Normalized values were imported into the R statistical environment21 for analyses. The differences in nor-
malized metabolite concentrations were tested for significance using a Kruskal-Wallis test, followed by post hoc 
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Nemenyi tests. Bonferroni correction was applied to account for multiple comparisons. Each metabolite and total 
lipid was scaled to a mean of 0 and a standard deviation of 1 in order to perform principal component analysis 
and cluster analysis and visualize the structure of the data. Initially, a classification model was created for medul-
loblastoma, ependymoma and pilocytic astrocytoma cases. Principal components accounting for 90% of the total 
variation were then subjected to LDA. The robustness of the resulting model was assessed using a 10-fold cross 
validation. This technique builds the classifier on 90% of the cases selected randomly and tests it on the remaining 
10% which therefore form an independent test set. The process is repeated 10 times so that all cases are included 
in a test set. A second model was created to incorporate the ATRT and to investigate the influence of adding rarer 
tumors to the analysis. Due to the low number of ATRT samples, a decision tree was used to classify samples as 
either embryonal or glial tumors, before attempting to classify the diagnosis. This model was validated using a 
leave-one-out cross validation, leading to each case being independently tested using a model created using the 
rest of the cohort.
Metabolic pathway analysis was conducted using the MetPA tool of Metaboanalyst 3.022, an online server 
allowing network analysis of the tumors to be performed. MetPA conducts pathway enrichment analysis and 
pathway topology analysis to identify metabolic pathways that are differentially activated in the samples of 
interest.
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
Histopathological reports. BCH histopathological reports were available via the hospitals reporting sys-
tem. The histopathological information for samples from other centres was requested through the CCLG tissue 
bank. For assessing the accuracy of current rapid intraoperative diagnosis, the rapid diagnosis was considered 
concordant if the diagnosis obtained via haematoxylin and eosin (H&E) stained smear preparations, frequently 
complemented by frozen sections, agreed with the final confirmed diagnosis for the case. Partial concordance 
was assigned when a distinct histopathological entity was diagnosed within a broader category, for example, an 
ependymoma described as a glial tumor.
Results
Cohort. In total, 83 samples were accrued, including 24 pilocytic astrocytomas, 18 ependymomas, 36 medul-
loblastomas and 5 ATRTs. The cohort features a male bias, in line with the fact that CNS tumors are known to be 
more prevalent in males1 (Supplementary Table 1). There is no statistical difference between the observed and 
expected numbers of males and females (χ2 p = 0.12).
Metabolic profiles of paediatric cerebellar tumors differ by tumor type. The HR-MAS protocol 
allowed the acquisition of high resolution metabolic profiles (Fig. 1). Of the 25 quantified metabolites in the 
analysis, 14 were significantly different between the three tumor types (Table 1). Medulloblastoma displayed 
significantly higher concentrations of ascorbate, aspartate, phosphocholine, taurine and lipids at 1.3 ppm and 
significantly lower glucose and scyllo-inositol. Ependymomas showed significantly higher concentrations of 
myo-inositol and glutathione and significantly lower leucine. Pilocytic astrocytoma tumors had significantly 
higher concentrations of glutamine and hypotaurine. When medulloblastomas and ATRTs were compared, cre-
atine was significantly lower in ATRTs (Supplementary Table 3).
Unsupervised hierarchical clustering shows four distinct clusters (Fig. 2). The highest split in the dendrogram 
separates embryonal tumors from glial tumors. Each sub cluster largely corresponds with a particular tumor type. 
In particular, it is interesting to note that ATRT cases cluster together within one of the four sub clusters.
Paediatric cerebellar tumors can be discriminated using linear discriminant analysis 
(LDA). The LDA model shows clear separation of the three main tumor types (Fig. 3). The first linear discrimi-
nant function separates the medulloblastoma and pilocytic astrocytoma cases. Metabolites important for identi-
fying medulloblastoma include phosphocholine, glycine, taurine and isoleucine. Glutamine, NAA, scyllo-inositol, 
hypotaurine and acetate are important for pilocytic astrocytoma classification. Ependymoma are separated from 
the other two tumor types by the second discriminant function. Metabolites important for ependymoma classifi-
cation include myo-inositol, glycerophosphocholine, glucose and alanine.
The robustness of the model was tested using a 10-fold cross validation. Ependymoma and medulloblastoma 
had the joint highest classification accuracy with 94.4% of cases correctly classified. Pilocytic astrocytoma had the 
lowest accuracy with 91.7% of cases being classified correctly (Table 2). The high accuracy shows the model does 
not over fit the data and retains generalizability.
Although this study has focused on the three most common childhood tumors presenting in the cerebellum, 
five ATRT tumors were added to see how tumor classification was affected and how accurately this minority 
tumor class could be classified. Using a binary classification model validated by a leave-one-out cross validation, 
classification accuracies of 60% for ATRT, 83.3% for medulloblastoma, 94.4% for ependymoma and 91.7% for 
pilocytic astrocytoma were obtained (Supplementary Fig. 1).
Histopathological discrimination of paediatric cerebellar tumors. Ependymoma had the lowest 
diagnostic accuracy with 10 of the 14 cases (71%) reporting a concordant diagnosis where intra-operative prepa-
rations were assessed (Table 2). The remaining 4 cases were partially concordant; these samples were described as 
gliomas or low grade gliomas.
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The pilocytic astrocytoma group were intermediate in the analysis, with 16 of 18 cases (89%) reporting a con-
cordant diagnosis where an intra-operative diagnosis was given. The remaining two cases were discordant and 
were diagnosed as medulloblastoma and ependymoma.
Figure 1. Example spectrum of a medulloblastoma acquired using HR-MAS. Metabolite assignments are 
shown along with their peak pattern. The resolution of the spectrum allows the accurate assignment and 
quantitation of a range of metabolites. Abbreviations: s - singlet, d – doublet, dd – doublet of doublets, t – triplet, 
m – multiplet, Ace – acetate, Ala – alanine, Asc – ascorbate, Asp – aspartate, Cho – Choline, Cr – Creatine, 
GABA - gamma-aminobutyric acid, Gln – glutamine, Glu – Glutamate, Gly – Glycine, GSH – glutathione, Htau 
– hypotaurine, Iso – Isoleucine, Leu – leucine, mIns - myo-inositol, sIns - scyllo-inositol, Tau – taurine, Val - 
valine.
Metabolite
Mean normalized concentration Kruskall-
Wallis P 
value
Bonferroni 
corrected P 
value
Nemenyi post hoc P values
Medulloblastoma Ependymoma
Pilocytic 
astrocytoma
Med vs 
Epen Med vs PA
Epen vs 
PA
Ascorbate 0.039 0.018 0.022 3.2 × 10−5 8.0 × 10−4 4.0 × 10−4 2.0 × 10−3 N.S
Aspartate 0.0076 0.0014 0.0009 2.8 × 10−5 7.0 × 10−4 8.6 × 10−3 1.0 × 10−4 N.S
Glucose 0.002 0.014 0.019 2.5 × 10−4 6.2 × 10−3 1.3 × 10−2 1.1 × 10−3 N.S
Glutamine 0.093 0.14 0.26 1.4 × 10−9 3.5 × 10−8 N.S 1.4 × 10−9 4.2 × 10−3
GPC 0.014 0.031 0.036 2.2 × 10−5 5.5 × 10−4 N.S 2.6 × 10−5 N.S
Glutathione 0.026 0.041 0.023 1.0 × 10−4 2.5 × 10−3 N.S 3.6 × 10−2 1.1 × 10−4
Hypotaurine 0.022 0.017 0.045 1.3 × 10−4 3.2 × 10−3 N.S 2.2 × 10−2 1.7 × 10−4
Leucine 0.0082 0.0014 0.0096 1.7 × 10−4 4.2 × 10−3 1.7 × 10−4 N.S 3.7 × 10−2
Myo inositol 0.12 0.28 0.13 2.0 × 10−7 5.0 × 10−6 6.5 × 10−7 N.S 4.1 × 10−5
NAA 0.013 0.0036 0.025 3.5 × 10−7 8.8 × 10−6 4.2 × 10−3 1.9 × 10−2 3.5 × 10−7
PCh 0.12 0.03 0.03 1.3 × 10−10 3.3 × 10−9 2.5 × 10−6 1.6 × 10−8 N.S
Scyllo inositol 0.0019 0.0072 0.008 1.2 × 10−5 3.0 × 10−4 2.3 × 10−4 8.0 × 10−4 N.S
Succinate 0.0024 0.0049 0.0099 7.7 × 10−5 1.9 × 10−3 N.S 7.9 × 10−5 N.S
Taurine 0.17 0.088 0.037 6.6 × 10−11 1.7 × 10−9 8.9 × 10−3 8.1 × 10−11 1.4 × 10−2
Table 1. Kruskal Wallis tests identify 14 metabolites with concentrations that vary according to diagnosis. Post 
hoc tests identify which tumors have significantly different metabolite concentrations. Abbreviations – GPC, 
glycerophosphocholine; NAA, N-acetylaspartate; PCh, phosphocholine.
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Figure 2. Hierarchical clustering of paediatric cerebellar tumors based on metabolite concentrations. The 
highest split in the figure separates glial tumors from embryonal tumors. The subsequent split broadly separates 
the tumor types. Abbreviations: MB, medulloblastoma; EP, ependymoma; PA, pilocytic astrocytoma; ATRT, 
Atypical Teratoid/Rhabdoid Tumor.
Figure 3. The output of the linear discriminant analysis. (A) The LDA scatterplot displays clear separation 
of the ependymoma (n = 18), medulloblastoma (n = 36) and pilocytic astrocytoma (n = 24). The decision 
boundaries, shown by the solid line, define the regions of the plot for each tumor type. (B) The loadings for the 
first discriminant function. The metabolites with more negative loadings are important for medulloblastoma 
classification, whilst metabolites with more positive loadings are important for pilocytic astrocytoma 
classification. (C) The loadings for the second discriminant function. Metabolites with more positive loadings 
are important for separating ependymoma from the other two tumor types. Abbreviations – GABA, gamma-
aminobutyric acid; GPC, glycerophosphocholine; NAA, N-acetylaspartate; PCh, phosphocholine.
Classification accuracy of linear discriminant analysis
Ependymoma Medulloblastoma
Pilocytic 
astrocytoma % correct
Ependymoma 17 0 1 94.4
Medulloblastoma 1 34 1 94.4
Pilocytic astrocytoma 1 1 22 91.7
Rapid intraoperative histopathological diagnostic accuracy
Number of 
concordant 
diagnoses
Number of partially 
concordant 
diagnoses
Number of 
discordant 
diagnoses % concordant
Ependymoma 10 4 0 71.4
Medulloblastoma 28 1 2 90.3
Pilocytic astrocytoma 16 0 2 88.9
Table 2. The cross-validated diagnostic accuracy of the LDA for the three cerebellar tumor types. The linear 
discriminant classifier achieved accuracies greater than 90% for all three tumor types. Furthermore, for all 
tumor types, the classification accuracy was greater than the rapid intraoperative diagnostic examination; 
however, this appears to be due to partial concordance as opposed to an incorrect diagnosis.
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Medulloblastoma had the highest rate of concordant diagnoses using rapid intraoperative preparations, with 
28 of the 31 cases (90%). Two cases were discordant; one case was thought to represent an astrocytoma whilst 
the other a low grade glioma. The remaining case was partially concordant as it was diagnosed as a malignant 
intrinsic tumor. Of the 5 ATRT cases, 2 (40%) reported a concordant diagnosis. The remaining 3 were partially 
concordant; two were given with a medulloblastoma differential diagnosis and one was described as a high grade 
tumor.
The individual metabolite profile classification results of the partially concordant and discordant cases were 
reviewed. All partially concordant and discordant pilocytic astrocytoma, ependymoma and medulloblastoma 
were correctly classified by the LDA. Of the 3 partially concordant ATRT cases, 1 was correctly classified by the 
decision tree, whilst 1 was classified as an ependymoma and the other as a medulloblastoma.
Metabolic pathways are altered between the three main tumor types. The normalized metabo-
lite concentrations were submitted to the MetPA online tool22 for pathway analysis to identify altered pathways 
between the tumor groups. The four most statistically differentially activated pathways were: glycerophospholipid 
metabolism; taurine and hypotaurine metabolism; alanine, aspartate and glutamate metabolism; and arginine 
and proline metabolism (Table 3). The alanine, aspartate and glutamate had the highest impact factor, indicating 
that the key metabolites in this pathway were present in the analysis and that the tumors use these metabolites 
differently relative to each other. Conversely, arginine and proline metabolism had the lowest impact factor of the 
four pathways, indicating a lack of key metabolite quantification. Post hoc tests revealed that glycerophospholipid 
metabolism is enriched in medulloblastoma relative to the other two tumor types.
Discussion
This work has demonstrated that the metabolite profiles of ex vivo tumor tissue are different for the three major 
paediatric tumors of the cerebellum through unsupervised analysis, and are sufficiently different that robust diag-
nostic classifiers can be built with high rates of diagnostic accuracy. Also, we have shown that metabolic pathway 
analysis using quantified metabolites can identify pathways with altered activity between tumor types giving the 
potential for future targeted treatments. Given the ease of sample handling, the short data acquisition time and 
potential for automated analysis, the technique could find a role in aiding clinical diagnosis. Although not inves-
tigated for the samples in this work, HR-MAS is a non-destructive method and prior studies suggest that post 
analysis tissue is of suitable quality for subsequent histological and molecular analysis23,24. HR-MAS and in vivo 
MRS share the same technical principles, therefore tissue studies such as ours can be used to inform and refine 
non-invasive spectroscopic examination.
Alternative tissue based techniques have been proposed in the literature to aid the real time surgical manage-
ment of patients. The alternative metabolomic technique, mass spectrometry, has been shown to have potential 
with regards to diagnosing pediatric brain tumors25. Unlike HR-MAS, the metabolites must be extracted from 
the tissue rendering it unavailable for further study. Raman spectroscopy and optical coherence tomography are 
two non-metabolomic techniques that have been shown to have intra-operative diagnostic potential for brain 
tumors26,27. Both are limited by the tissue penetrance they can achieve. Due to their intrinsic technical properties, 
none of the above three techniques can be translated to a non-invasive methodology.
The ex vivo spectroscopy provides further evidence for characteristic metabolite profiles of these tumor types. 
In particular, high phosphocholine and taurine in medulloblastoma, high glutamine in pilocytic astrocytoma 
and high myo-inositol in ependymoma tumors were important for tumor identification. Previous work28 has 
compared the metabolite profiles of paediatric cerebellar tumors and our studies agree on most of the key charac-
teristic metabolite markers. Our study showed that myo-inositol is higher in concentration in ependymoma than 
medulloblastoma, agreeing with in vivo MRS but contrary to the findings reported in Cuellar-Baena et al.28 This 
is likely to be a consequence of the larger sample size in our study particularly for ependymoma. Furthermore, 
our study constructs an accurate and robust classifier with clinical utility and identifies metabolic pathways with 
different activity.
It has been shown that the most concentrated metabolites in brain tumors are quantifiable in vivo and corre-
late with the ex vivo spectroscopy15. Further technical development of in vivo MRS has shown that it is possible to 
accurately measure the concentration of metabolites with overlapping resonances29–31. Therefore, the metabolites 
described in this work have the potential be to be used as diagnostic markers.
The decision boundaries clearly separate the tumor types, with only two cases lying outside the decision 
boundary for their respective tumor type. It is interesting to note the loadings of the discriminant analysis reflect 
Metabolic pathway
Total number 
of compounds Hits P value Impact
Pairwise P values
Med vs Epen Med vs PA Epen vs PA
Glycerophospholipid metabolism 39 4 5.5 × 10−20 0.20 1.0 × 10−8 8.6 × 10−11 N.S.
Taurine and hypotaurine metabolism 20 4 3.6 × 10−15 0.44 1.9 × 10−3 9.1 × 10−9 4.9 × 10−5
Alanine, aspartate and glutamate metabolism 24 7 5.2 × 10−15 0.81 6.0 × 10−3 3.2 × 10−11 2.0 × 10−4
Arginine and proline metabolism 77 5 1.3 × 10−14 0.087 5.9 × 10−3 4.8 × 10−11 2.5 × 10−4
Table 3. The top 4 most significantly different pathways between the three most common cerebellar tumors. 
Glycerophospholipid metabolism is enriched in medulloblastoma compared to the other two tumor types. The 
alanine, aspartate and glutamate metabolism pathway has the highest topological metric, and it is likely that this 
pathway is strongly associated with tumor type.
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the findings of the average concentrations of the metabolites discussed previously, confirming that typical spec-
troscopic features can be used to separate the three tumor types. The classification algorithm is robust against 
overfitting, as demonstrated by the high classification accuracy after 10-fold cross validation.
Whilst our preliminary results for ATRT classification are encouraging, incorporation of rare tumor types may 
require statistical oversampling methods to compensate for the large differences in tumor frequency32. ATRT are 
rare but important tumors in childhood; they represent the majority of the tumors in the cerebellum which are 
not medulloblastomas, pilocytic astrocytomas or ependymomas and commonly represent a diagnostic dilemma 
particularly with medulloblastoma33. They are particularly aggressive tumors with a very poor prognosis and for 
which it is essential that maximal resection is obtained and that adjuvant treatment is started as soon as possible. 
There is currently no rapid diagnostic test for this tumor group since diagnosis relies on immunohistochemical 
staining for INI1. On an interesting note, the classification accuracy for pilocytic astrocytoma and ependymoma 
remain the same when ATRTs are incorporated. Therefore, metabolite profiles are able to confidently identify and 
separate glial and embryonal tumors, which is important if the tumor in question is a rare entity.
HR-MAS has shown promise for examining tissue from several cancer types10,11, and may be used to comple-
ment the histological data. Indeed, some work has been published on the use of rapid metabolite profiling and 
its clinical application in the surgical management of tumors34 which reported histopathology matching tumor 
identification in 17 mins. With metabolism under the control of the oncogenic drivers, HR-MAS has the potential 
to identify tumor subgroups in a short time frame, as shown in adults with SDH mutated paraganglioma or phe-
ochromocytoma35 or IDH mutated gliomas36. HR-MAS also has the ability to identify novel metabolic subgroups 
which correlate with histopathological features. This was demonstrated in retinoblastoma where 3 clinicopatho-
logical subgroups were identified in which taurine, lipids and phosphosholine correlated with differentiation, 
necrosis and invasion respectively37. Other work performed using neuroblastoma tissue found taurine correlated 
with a worse prognosis whilst glutamine, myo-inositol and glycine was associated with stage I-II neuroblastoma38. 
Whilst our study has not attempted to classify tumors into recognized molecular subgroups, there is evidence 
that MRS is able to identify medulloblastoma molecular subgroup39 and this warrants further investigation. Brain 
tumors in adults are different in terms of the types of tumors and their anatomical location40. HR-MAS has been 
used to predict grade of astrocytic tumors41, and assess the extent of microheterogeneity in glioblastoma23.
To put the accuracy of the HR-MAS classification into context, a comparison was made with accuracy of cur-
rent rapid intraoperative assessment using clinical reports for the tissue used in this analysis. Rapid intraoperative 
testing consists of smear cytological preparations often complemented by frozen sections stained with H&E to 
assess the cytological aspect as well as architectural features42. This method is cheap, rapid without the need for 
expensive equipment and gives reasonably accurate results to guide surgical management decisions.
The results of our analysis broadly agree with published retrospective analyses of rapid intraoperative assess-
ment43,44; complete agreement of the rapid intraoperative assessment and final histological diagnosis is achieved 
in the majority of astrocytoma and medulloblastoma cases. Ependymoma, however, have a higher rate of partial 
concordance. Currently, the greatest prognostic marker for ependymoma is extent of surgical resection45, there-
fore it is imperative to identify ependymomas and optimize surgical treatment. Although there were no discord-
ant ependymoma diagnoses by intraoperative assessment in our study, the partially concordant diagnoses could 
include tumors for which a complete resection is far less important. HR-MAS may aid in the identification of such 
tumors in real time and improve surgical management when intraoperative H&E assessment is ambiguous. In 
support of this, the metabolite profiles of the partially concordant and discordant pilocytic astrocytoma, epend-
ymoma and medulloblastoma were not different from those of their respective tumor types. Metabolite profiles 
aided in the identification of one of the partially concordant ATRT cases, but not in the other two.
The pathway analysis identified metabolic pathways that were differentially activated between the three tumor 
types. Of these pathways, the alanine, glutamate and aspartate metabolic pathway had the highest impact factor. 
Therefore, it is likely that the biochemistry within this pathway is different between tumor groups. This pathway is 
closely linked to supplementing the tricarboxylic acid cycle through the conversion of amino acids to TCA cycle 
intermediaries46 and provides nitrogen for the de novo nucleotide synthesis47. Upregulation of glutamine catabo-
lising pathways has been linked to more aggressive, higher grade tumors which rely on glutaminolysis to support 
their increased proliferation48. Consequently, lower glutamine is observed in medulloblastoma and ependymoma 
compared to pilocytic astrocytoma.
Hypotaurine and taurine metabolism and glycerophospholipid metabolism also differed between the tumor 
types. The high concentration of taurine in embryonal tumors is likely related to their developmental stage when 
compared to the glial ependymoma and pilocytic astrocytoma, as high taurine concentration has been described 
in other paediatric embryonal CNS tumors37,49. Taurine has been shown to be important for neuronal stem cell 
proliferation and neurogenesis50,51 and the migration of neuronal cells from the external to the internal granular 
layer in the cerebellum52. Hypotaurine is a poorly understood metabolite whose function is not clear and warrants 
further study to elucidate its role in normal and neoplastic tissue.
Glycerophospholipid metabolism is primarily responsible for synthesizing components for cellular and orga-
nelle membranes. Alterations in choline metabolism is a hallmark of malignancies53. In brain tumors, increased 
concentration of choline containing compounds as detected by in vivo 1H MRS have been associated with higher 
grade54. In addition, 31P MRS has identified alterations in the ratios of phosphorylated choline metabolites 
between normal tissue and brain tumors18. This is supported by ex vivo work, where it was shown that phospho-
choline concentration correlated with grade, phospholipase C and choline kinase β expression55. These factors 
influencing synthesis may explain the observed increase in phosphocholine concentration in medulloblastoma 
tissue. As well as meeting the cells biosynthetic needs, this pathway is involved in intracellular signalling. The 
action of phospholipase C enzymes generates diacylglycerol and a free head group such as phosphocholine or 
phosphoinositol which act as secondary messengers. Our results suggest this pathway is enriched in medulloblas-
toma, and is an ideal candidate pathway for further examination to identify targeted therapies.
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The arginine and proline metabolism pathway was detected to be significantly different between the three 
tumor types. HR-MAS is not able to identify the very low abundance key metabolites in this pathway, leading to 
a low impact score and an inability to draw firm conclusions regarding this pathway. Further examination of the 
metabolic pathways using other more sensitive metabolomic approaches will improve the metabolome coverage 
and lead to a more comprehensive metabolic pathway analysis. This approach will be vital to gaining a complete 
understanding of how metabolism varies between these tumor types and identify potential treatment targets.
In conclusion, this study has shown that HR-MAS can detect characteristic metabolic profiles from small 
pieces of fresh frozen biopsy tissue which can be used to build an accurate and clinically relevant classifier, with 
potential for future development as an intraoperative technique for improved surgical management. It has also 
shown that biological information can be extracted and differentially activated metabolic pathways can start to 
be identified. This may lead to improved insights into the metabolism of these tumors and the development of 
targeted therapies.
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